Terms: = Kidney tumors AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155
212 results:
1. Dual-loss of pbrm1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract] [Full Text] [Related]
2. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract] [Full Text] [Related]
3. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract] [Full Text] [Related]
4. Effects of Purine Metabolism-Related
Yin W; Wang JH; Liang YM; Liu KH; Chen Y; Chen YS
Front Biosci (Landmark Ed); 2023 Dec; 28(12):354. PubMed ID: 38179759
[TBL] [Abstract] [Full Text] [Related]
5. pbrm1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract] [Full Text] [Related]
6. Genetic Profiling Uncovers Genome-Wide Loss of Heterozygosity and Provides Insight into Mechanisms of Sarcomatoid Transformation in Chromophobe Renal Cell Carcinoma.
Collins K; Acosta AM; Siegmund SE; Cheng L; Hirsch MS; Idrees MT
Mod Pathol; 2024 Feb; 37(2):100396. PubMed ID: 38043790
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma.
Sellner F; Compérat E; Klimpfinger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003482
[TBL] [Abstract] [Full Text] [Related]
8. Knockdown of
Xin H; Tang Y; Jin YH; Li HL; Tian Y; Yu C; Zhao ZJ; Wu MS; Pan YF
Cell Adh Migr; 2023 Dec; 17(1):1-14. PubMed ID: 37749865
[TBL] [Abstract] [Full Text] [Related]
9. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.
Nyman J; Denize T; Bakouny Z; Labaki C; Titchen BM; Bi K; Hari SN; Rosenthal J; Mehta N; Jiang B; Sharma B; Felt K; Umeton R; Braun DA; Rodig S; Choueiri TK; Signoretti S; Van Allen EM
Cell Rep Med; 2023 Sep; 4(9):101189. PubMed ID: 37729872
[TBL] [Abstract] [Full Text] [Related]
10. Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma.
Wang H; Yang Z; He X; Guo F; Sun H; Xu S; Xu C; Wang Z; Wen H; Teng Z; Wang Y; Han Z
BMC Cancer; 2023 Aug; 23(1):804. PubMed ID: 37641032
[TBL] [Abstract] [Full Text] [Related]
11. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
12. Comparison and validation of different risk models for papillary renal cell carcinoma.
Lin H; Sun Q; Li Z; Zheng J; Zhang X; Xiong Y; Chen H; Hou Y; Xi W; Lin J
Urol Oncol; 2023 Aug; 41(8):358.e1-358.e7. PubMed ID: 37394414
[TBL] [Abstract] [Full Text] [Related]
13. Relationship between body composition and pbrm1 mutations in clear cell renal cell carcinoma: a propensity score matching analysis.
Demirel E; Dilek O
Rev Assoc Med Bras (1992); 2023; 69(5):e20220415. PubMed ID: 37222312
[TBL] [Abstract] [Full Text] [Related]
14. Novel genetically engineered mouse models for clear cell renal cell carcinoma.
van der Mijn JC; Laursen KB; Fu L; Khani F; Dow LE; Nowak DG; Chen Q; Gross SS; Nanus DM; Gudas LJ
Sci Rep; 2023 May; 13(1):8246. PubMed ID: 37217526
[TBL] [Abstract] [Full Text] [Related]
15. pbrm1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma.
Yao X; Hong JH; Nargund AM; Ng MSW; Heng HL; Li Z; Guan P; Sugiura M; Chu PL; Wang LC; Ye X; Qu J; Kwek XY; Lim JCT; Ooi WF; Koh J; Wang Z; Pan YF; Ong YS; Tan KY; Goh JY; Ng SR; Pignata L; Huang D; Lezhava A; Tay ST; Lee M; Yeo XH; Tam WL; Rha SY; Li S; Guccione E; Futreal A; Tan J; Yeong JPS; Hong W; Yauch R; Chang KT; Sobota RM; Tan P; Teh BT
Nat Cell Biol; 2023 May; 25(5):765-777. PubMed ID: 37095322
[TBL] [Abstract] [Full Text] [Related]
16. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract] [Full Text] [Related]
17. Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study.
Liu DH; Dani KA; Reddy SS; Lei X; Demirjian NL; Hwang DH; Varghese BA; Rhie SK; Yap FY; Quinn DI; Siddiqi I; Aron M; Vaishampayan U; Zahoor H; Cen SY; Gill IS; Duddalwar VA
Oncology; 2023; 101(6):375-388. PubMed ID: 37080171
[TBL] [Abstract] [Full Text] [Related]
18. Integrated glycoproteomic characterization of clear cell renal cell carcinoma.
Lih TM; Cho KC; Schnaubelt M; Hu Y; Zhang H
Cell Rep; 2023 May; 42(5):112409. PubMed ID: 37074911
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
Wu Y; Terekhanova NV; Caravan W; Naser Al Deen N; Lal P; Chen S; Mo CK; Cao S; Li Y; Karpova A; Liu R; Zhao Y; Shinkle A; Strunilin I; Weimholt C; Sato K; Yao L; Serasanambati M; Yang X; Wyczalkowski M; Zhu H; Zhou DC; Jayasinghe RG; Mendez D; Wendl MC; Clark D; Newton C; Ruan Y; Reimers MA; Pachynski RK; Kinsinger C; Jewell S; Chan DW; Zhang H; Chaudhuri AA; Chheda MG; Humphreys BD; Mesri M; Rodriguez H; Hsieh JJ; Ding L; Chen F
Nat Commun; 2023 Mar; 14(1):1681. PubMed ID: 36973268
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Genomic Profiling of NF2-Mutated kidney tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract] [Full Text] [Related]
[Next]
